AZNAstraZenecaSigning up patients
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Platinum-sensitive Relapsed Epithelial Ovarian Cancer · Platinum-sensitive Relapsed Fallopian Tube Cancer · Platinum-sensitive Relapsed Primary Peritoneal Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 600 (planned)
- Started
- Sep 24, 2026
- Main results expected
- Sep 29, 2028
- Fully finished
- Oct 30, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07816666 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC